-
Two-stage approach for risk estimation of fetal trisomy 21 and other aneuploidies using computational intelligence systems.
Neocleous AC, Syngelaki A, Nicolaides KH, Schizas CN.
Ultrasound Obstet Gynecol 2018;51:503-508. pdf -
Expanded conventional first trimester screening.
Carmichael JB, Liu HP, Janik D, Hallahan TW, Nicolaides KH, Krantz DA.
Prenat Diagn 2017;37:802-807. pdf -
Sphenofrontal distance on three-dimensional ultrasound in euploid and trisomy-21 fetuses at 16-24 weeks' gestation.
Cossellu G, Persico N, D'Ambrosi F, Carbone F, Fabietti I, Boito S, Farronato G, Fedele L, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:177-80. pdf -
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
Meta-analysis of second-trimester markers for trisomy 21.
Agathokleous M, Chaveeva P, Poon LC, Kosinski P, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;41:247-61. -
First-trimester combined screening for trisomy 21 at 8-13 weeks.
Wright D, Spencer K, Kagan K, Tørring N, Petersen O, Christou A, Kallikas J, Nicolaides K.
Ultrasound Obstet Gynecol 2010;36:404-11. -
Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing.
Kagan K, Staboulidou I, Cruz JJ, Wright D, Nicolaides K.
Ultrasound Obstet Gynecol 2010;36:542-7. -
Prospective validation of first-trimester combined screening for trisomy 21.
Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2009;34:14-8. -
Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21.
Kagan KO, Wright D, Etchegaray A, Zhou Y, Nicolaides KH.
Ultrasound Obstet Gynecol 2009;33:657-64. -
Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:618-24. -
Choroid plexus cyst, intracardiac echogenic focus, hyperechogenic bowel and hydronephrosis in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
Dagklis T, Plasencia W, Maiz N, Duarte L, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:132-5. -
First-trimester screening for trisomy 21 using nuchal translucency and nasal bone evaluations in a selected and an unselected population.
Sonek J, Cicero S, Nicolaides K.
Am J Obstet Gynecol 2007;196:19. -
Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH.
Ultrasound Obstet Gynecol 2006;27:151-5. -
Screening for trisomy 21 in monochorionic twins by measurement of fetal nuchal translucency thickness.
Vandecruys H, Faiola S, Auer M, Sebire N, Nicolaides KH.
Ultrasound Obstet Gynecol 2005;25:551-3. -
Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O.
Ultrasound Obstet Gynecol 2005;25:221-6. -
Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21.
Nicolaides KH, Chervenak FA, McCullough LB, Avgidou K, Papageorghiou A.
Am J Obstet Gynecol 2005;193:322-6. -
Down syndrome screening marker levels in women with a previous aneuploidy pregnancy.
Cuckle HS, Spencer K, Nicolaides KH.
Prenat Diagn 2005;25:47-50. -
Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies.
Avgidou K, Papageorghiou A, Bindra R, Spencer K, Nicolaides KH.
Am J Obstet Gynecol 2005;192:1761-7. -
Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
Spencer K, Nicolaides KH.
BJOG 2003;110:276-80. -
Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Cicero S, Bindra R, Rembouskos G, Spencer K, Nicolaides KH.
Prenat Diagn 2003;23:306-10.